Relationship between cyclooxygenase-2 inhibition and thrombogenesis (Q35750211)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on March 2004

Language	Label	Description	Also known as
English	Relationship between cyclooxygenase-2 inhibition and thrombogenesis	scientific article published on March 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

Europe PubMed Central

Relationship between cyclooxygenase-2 inhibition and thrombogenesis (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Wangde Dai

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Robert A Kloner

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Journal of Cardiovascular Pharmacology and Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

51-59

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Prostaglandins and leukotrienes: advances in eicosanoid biology

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Biomedicine. Back to an aspirin a day?

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Prostaglandin H synthase and vascular function

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

The clinical potential of cyclooxygenase-2-specific inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Role and regulation of cyclooxygenase-2 during inflammation

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Do human platelets express COX-2?

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Antiarrhythmic drugs and torsade de pointes

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Primary endothelial dysfunction: atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

PGI2 production by rat blood vessels: Diminished prostacyclin formation in veins compared to arteries

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Systemic nature of endothelial dysfunction in atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Aspirin improves endothelial dysfunction in atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

COX inhibitors and thromboregulation

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Effects of nonsteroidal anti-inflammatory therapy on platelets

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

New trends in thromboxane and prostacyclin modulators

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Prostaglandins and prostaglandin inhibitors in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

The vulnerable plaque and acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Inflammation in acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Cyclooxygenase-2 inhibition and cardiovascular events

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Pharmacoepidemiology and rheumatic diseases: 2001-2002.

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients

1 reference

https://api.crossref.org/works/10.1177%2F107424840400900I108

21 January 2018

Identifiers

10.1177/107424840400900I108

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35750211&oldid=1585149274"